AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)

CAPS Rating: 2 out of 5

Results 1 - 7 of 7

Recs

0
Member Avatar pchop12316 (75.51) Submitted: 5/22/2015 10:14:14 AM : Underperform Start Price: $2.49 AVEO Score: +7.08

more pessimistic then optimistic

Recs

2
Member Avatar zzlangerhans (99.79) Submitted: 12/24/2014 2:30:22 AM : Underperform Start Price: $0.86 AVEO Score: -166.39

After closing yet another failed bet on Aveo, I'd be surprised if I ever went long on this stock again. Then again, I have a bad habit of repeating the same stupid mistakes over and over. Aveo is a classic value trap, where a market cap lower than cash ropes in the dopes but the company never generates a positive catalyst to reverse the downward momentum. Meanwhile, an unrelenting burn continues to drag the cash downward to keep pace with the declining share price. Where will it end? Either with bankruptcy or a reverse split so that the process can continue ad infinitum.

I've concluded there is low likelihood of meaningful positive developments from the pipeline. Tivozanib appears to be dead except for a insiginficant licensing deal to Ophthotech. Aveo claims they will initiate a proof of concept trial of ficlatuzumab and erlotinib in NSCLC before the end of the year, but prior data for that indication has been unimpressive and I'd be surprised to see any catalysts from that trial in 2015. AV-203 development seems to be on hold pending a partnership which is unlikely to materialize, and clinical trials of uninspiring anti-cachexia candidate AV-380 won't begin until at least H2 2015.

Recs

0
Member Avatar Aurum (76.13) Submitted: 7/29/2014 12:48:52 PM : Outperform Start Price: $1.26 AVEO Score: +75.77

Part of a broader pick of micro cap biotechs with encouraging preliminary clinical trial data and significant upside.

Recs

0
Member Avatar rossodell3 (< 20) Submitted: 4/16/2014 7:29:44 AM : Outperform Start Price: $1.35 AVEO Score: +56.27

I was on an Aveo trial drug and it did it's job quite well I tried the other drugs and switched and now cancer free. I checked back with some that i got to know and they lost their battle so i thank with alittle time and with out other drug company intferance Aveo will grow in the next year Good Luck in the fight with this terrible diesase

Recs

0
Member Avatar NoblyNaive (83.25) Submitted: 5/1/2013 2:37:31 PM : Outperform Start Price: $5.49 AVEO Score: -92.04

Short term play, based on chart action and news that this company is not dead yet: Near 52-week (or is it longer?) low, after approx 33% drop basd on bad news. The plan: Expect lots of price chop, so wait until the volatility takes it high and get out before news on tests breaks next month.

Recs

0
Member Avatar EclecticRecluse (80.64) Submitted: 2/22/2011 12:58:10 PM : Underperform Start Price: $13.89 AVEO Score: +144.65

Poor Forward Earnings Estimate

Recs

0
Member Avatar 1963spencer (43.27) Submitted: 10/20/2010 11:02:11 AM : Outperform Start Price: $15.24 AVEO Score: -165.80

I have RCC. Stinks but I am all for any biotech company that takes the time to perhaps find a cure. Phase 3 trials are looking good. So yea they are going to get any financing needed. Look forward to mid 2011!

Results 1 - 7 of 7

Featured Broker Partners


Advertisement